
HCPLive 5 Stories in Under 5: Week of 04/06
Key Takeaways
- AI tools may improve guideline adherence and decision-making in virtual urgent care, but clinician oversight is essential.
- The FDA's acceptance of the BLA for ONS-5010 advances it toward potential approval for wet AMD treatment.
An audio recap of the top 5 stories in healthcare news from the week of 03/31-04/06.
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for March 31-April 6, 2025:
A Cedars-Sinai study suggests AI tools may enhance guideline adherence and decision-making quality in virtual urgent care, though clinician oversight remains essential.
The FDA has accepted a resubmitted BLA for ONS-5010, a proposed ophthalmic formulation of bevacizumab for wet AMD, advancing it toward potential approval.
A retrospective study linked lower socioeconomic status to reduced access to preemptive kidney transplants in pediatric patients, underscoring ongoing disparities in care.
The FDA has cleared the Dexcom G7 CGM system for 15-day use in adults, offering extended wear and continued improvements in diabetes monitoring technology.
New phase 3 data show once-daily icotrokinra improves skin clearance and maintains a favorable safety profile in adolescents with moderate-to-severe plaque psoriasis.
























































































